Wegovy vs Mounjaro: Mechanism, Pricing & Key Differences
Wegovy V Mounjaro UK: Understanding the Core Mechanisms
When comparing Wegovy v Mounjaro UK options, the fundamental difference lies in their mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural fullness hormone to reduce appetite and promote satiety after smaller meals. Mounjaro contains tirzepatide, a dual agonist targeting both GLP-1 and GIP receptors, offering a different approach to weight management through multiple pathways.
Both prescription-only medicines work by influencing brain appetite centres, but their receptor targets create distinct therapeutic profiles. Wegovy's single-pathway approach has extensive clinical validation through the STEP trial programme, whilst Mounjaro's dual mechanism represents a newer approach to metabolic regulation. Your prescriber can help determine which mechanism aligns better with your individual health profile and treatment goals during the clinical assessment process.
Wegovy vs Mounjaro UK Pricing: Complete Cost Comparison
Understanding the pricing structure for Wegovy vs Mounjaro helps inform your treatment decision. Wegovy follows a 5-dose escalation schedule starting at £79.99 for the 0.25mg starter dose (weeks 1-4), progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to the maintenance dose of 2.4mg at £209.99. New customers can apply code FIRST40 at checkout, whilst returning patients use DOSE25 to reach these final prices.
Mounjaro pricing varies based on its 6-dose escalation schedule, with different cost considerations for its 2.5mg to 15mg dosing range. Both treatments offer bundle options for convenience, such as Wegovy's Intro Trio (0.25mg, 0.5mg & 1mg) for £299.99, providing a seamless progression through initial doses. The choice between individual pens versus bundles depends on your preference for ordering frequency and supply security rather than cost savings.
Clinical Evidence for Wegovy V Mounjaro UK Treatments
Wegovy's efficacy is supported by the comprehensive STEP clinical trial programme, with STEP 1 showing patients achieving approximately 15% average weight loss at 68 weeks when combined with diet and exercise modifications. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major cardiovascular events, adding important safety and efficacy data for this prescription-only medicine.
Mounjaro's clinical evidence comes from the SURMOUNT trial series, though direct head-to-head comparisons between the two treatments require careful interpretation due to different trial designs and patient populations. Both treatments have received MHRA approval for weight management in adults with BMI ≥30, or BMI ≥27 with weight-related comorbidities, ensuring regulatory validation for UK prescribing.
How Wegovy Works: GLP-1 Mechanism Explained
Wegovy's semaglutide acts as a GLP-1 receptor agonist, binding to the same receptors as your body's natural incretin hormone GLP-1. This activation triggers several physiological responses including delayed gastric emptying, enhanced glucose-dependent insulin secretion, and most importantly for weight management, reduced food intake through central appetite suppression. The weekly injection maintains consistent therapeutic levels, eliminating the need for daily dosing whilst providing sustained appetite control. Clinical studies suggest this mechanism may also reduce food cravings by modulating reward pathways in the brain, though individual responses vary. The FlexTouch pen delivery system ensures accurate dosing throughout the 5-stage escalation protocol, from initial 0.25mg doses through to 2.4mg maintenance therapy.
Wegovy vs Mounjaro UK Ordering: Streamlined Assessment Process
Obtaining either Wegovy or Mounjaro through EverydayMeds follows our standardised 3-minute online clinical assessment, designed to gather essential medical history and ensure prescribing safety. Our qualified prescribers review applications within 3 working days (or 24 hours with express service), evaluating BMI criteria, contraindications, and treatment suitability for your individual circumstances. Once approved, your chosen treatment ships via next-day cold-chain delivery, maintaining the required 2-8°C temperature throughout transit. This process ensures both treatments receive the same level of clinical oversight, whether you're starting Wegovy's semaglutide therapy or beginning Mounjaro's tirzepatide regimen. Our GPhC-registered pharmacy (GPhC #9012878) maintains full regulatory compliance for both prescription-only medicines, providing confidence in treatment authenticity and storage integrity.
Storage Advantages: Wegovy V Mounjaro UK Practical Considerations
Storage requirements present a key practical difference when comparing Wegovy vs Mounjaro options for UK patients. Wegovy pens can remain at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit, offering superior travel flexibility and convenience. Both treatments require refrigeration at 2-8°C before first use, but Wegovy's extended temperature tolerance makes it more suitable for patients with irregular schedules, frequent travel, or limited refrigeration access. The FlexTouch pen system provides clear dose indicators and safety features, whilst the once-weekly injection schedule applies to both treatments. Remember that opened pens should be discarded after 6 weeks (Wegovy) or as specified in Mounjaro's patient information leaflet, regardless of remaining medicine, to ensure sterility and potency. Proper storage maintains efficacy throughout your dose escalation journey, from starter doses through maintenance therapy.
Wegovy vs Mounjaro UK: Dose Escalation and Flexibility Differences
The dosing schedules for Wegovy v Mounjaro UK treatments follow different escalation patterns that may suit different patient preferences and tolerability profiles. Wegovy's 5-dose protocol spans 16 weeks to reach maintenance therapy, with clearly defined 4-week intervals at each strength, providing a gradual adjustment period that many patients find manageable. Mounjaro offers 6 dose strengths with more flexible escalation timing, potentially allowing faster progression to higher doses based on individual response and tolerance.
This flexibility difference becomes important for patients who experience side effects or need slower titration schedules. Wegovy's structured approach provides predictability, whilst Mounjaro's additional dose options offer more personalisation potential. Both treatments emphasise the importance of not skipping dose escalation steps, as this increases the likelihood of gastrointestinal side effects and reduces long-term adherence to therapy.
Choose Your Wegovy V Mounjaro UK Treatment with Expert Guidance
Both Wegovy and Mounjaro are available from EverydayMeds with the same high standard of clinical oversight and pharmacy care, ensuring you receive expert guidance regardless of which treatment proves most suitable. Our prescribers consider factors including your medical history, lifestyle requirements, storage preferences, and dosing schedule preferences when recommending between these prescription-only medicines. New customers can begin their assessment today using code FIRST40 for optimal pricing, whilst existing patients benefit from DOSE25 discounts on their chosen treatment. The decision between Wegovy's proven GLP-1 approach and Mounjaro's dual-receptor mechanism should be made collaboratively with qualified healthcare professionals who understand your individual circumstances. Visit https://everydaymeds.co.uk/collections/weight-loss to start your clinical assessment and discover which treatment aligns best with your weight management goals alongside your reduced-calorie diet and increased physical activity programme.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
